Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1

2(40.0%)

Phase 3

2(40.0%)

Phase 2

1(20.0%)

5Total

Phase 1(2)

Phase 3(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT04757636Phase 3Terminated

OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)

Role: lead

NCT04757610Phase 3Terminated

OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)

Role: lead

NCT03397264Phase 1Completed

A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema

Role: lead

NCT03345082Phase 2Completed

A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD

Role: lead

NCT02543229Phase 1Completed

Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD

Role: lead

All 5 trials loaded